1.
The costs and effects of Regranex® in the treatment of diabetic feet ulcera (in Dutch)
2.
3.
Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands
Osteoporosis in the Netherlands; A burden of illness study commissioned by Merck Sharp & Dohme
Postmenopausal hormone therapy: Less favourable risk-benefit ratios in healthy Dutch women
One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial